WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
SJIF Impact Factor 8.084
Volume 12, Issue 22, 803-818. Review Article ISSN 2277–7105

THE SYSTEMIC REVIEW ON STEM CELL THERAPY FOR SPINAL CORD INJURY

Nikita Bhosale[1]*, Shubhangi Manikpuriya[2] and Dr. Gajanan Sanap[3]

Student[1], Assistant Professor[2] and Principal[3]

Late Bhagirathi Yashwantarao Patharikar Collage of Pharmacy India.

Article Received on
31 October 2023,

Revised on 20 Nov. 2023,
Accepted on 11 Dec. 2023

DOI: 10.20959/wjpr202322-30698

***Corresponding Author**
Nikita Bhosale
Student, Late Bhagirathi Yashwantarao Patharikar Collage of Pharmacy India.

ABSTRACT

Devastating outcomes for patients are possible with spinal cord injuries. In this in-depth review paper, we covered the epidemiology of spinal cord injuries and the neurologic exam findings that indicate primary and secondary injury development. The common theory of how nerve damage occurs is followed by the development of novel therapeutic strategies and their applicability to enhancing results. The condition is complex, and there are numerous management considerations. Additionally, it requires scientific research and innovation in bothpharmaceuticals and devices.

KEYWORDS: Spinal cord injury neural stem cells, Bone narrow derived mesenchyme stem cells, adipose-derived stem cells, embryonic stem cells. stem cell therapy adult. neural stem cell.

INTRODUCTION

The most common neurological condition in the world, spinal cord injury has a negative impact on the spinal cord and is caused by traumatic accidents. Currently, neurorestorative strategies, such as cell therapy (stem cell product mature functionally differentiated cell derived cell therapy product according classification United States Food and Drug Administration it is reported spinal cord injury young population high but recent year elderly population upward trend), are being used to treat the devastating condition of spinal cord injury, which results in high morbidity and mortality.[1]

1. Pathophysiology of spinal cord injury

Primary injury and secondary injury make up the pathophysiology of spinal cord damage.

1.1. Primary injury: The release of neurotoxin compounds and inflammatory mediators, which lead to neuronal and oligonucleotide cell death, results from the primary insult, whichis a direct physical injury to the spinal cord.[2-3]

1.2. Secondary injury: Secondary pathological injury is complicated cellular damage that develops over hours, days, and weeks. This damage includes loss of myelin, axon degeneration, and glial scar development, all of which prevent spontaneous regeneration and result in degeneration and functional loss.[4-5] Some experimental rat models of SCI reproduce the typical pathology of mortal SCI, including the extradural contraction, bruise, and crush models in rats SCI is classified depending on the time ceased from the original injury acute, within several days of SCI; subacute, one to two weeks after injury; or habitual, four weeks or further after injury. As bandied below, experimental cell transplantation strategies have generally been more effective in the subacute stage compared with the acute stage or the habitual stage, characterized by glial scarring and other inhibitory.[6]



Fig. no. 1: Typical Pathology of Human Spinal Cord Injury.

2. EPIDEMIOLOGY

Worldwide, the periodic prevalence of SCI is 15 – 40 cases per million people In Canada, the Rick Hansen Institute estimates there are presently 85,000 people living with SCI, with further than 4,000 new cases per time], and in the United States, the Christopher and Dana Reeve Foundation estimates a frequency of over 1 million cases with SCI and further than 12,000 new cases each time The primary causes of traumatic SCI are motor vehicle crashes, sports and recreation injuries, falls at home, and trauma at work. In youthful grown-ups, males are four times more likely than ladies to sustain an SCI Injury prevalence shows a bimodal distribution, with the loftiest prevalence in adolescents and youthful grown-ups, with further than partial aged 16 – 30 times old. The alternate prevalence peak is in aged grown-ups, primarily as a result of cascade, and the growing population has increased the average age of injury.



Fig. no. 2: Cell based strategies for spinal cord injury treatment3.Source of stem cells.

3.1. Embryonic Stem Cells As their name suggests they're deduced from embryos (blastocyst) that develop from eggs that have been fertilized in vitro — in an in vitro fertilization clinic — and also bestowed for exploration purposes with informed concurrence of the factors Growing embryonic stem cells in the laboratory[7-8] Growing cells in the laboratory is known as cell culture.[9] mortal embryonic stem cells are insulated by transferring the inner cell mass into a plastic laboratory culture dish that contains a nutrient broth known as culture medium. The cells divide and spread over the face of the dish.

3.2 Adult stem cell: An adult stem cell is an undifferentiated cell set up among discerned cells in a tissue or organ, can renew itself and can separate to yield the major technical cell types of the tissue or organ. The primary places of adult stem cells in a living organism are to maintain and repair the tissue in which they're set up.

4. Mechanism of SC therapy for spinal cord injury



Fig. 3: Stem Cell Therapy Use In Spinal Cord Injury.

4.1. Neurotropic and regenerative effect

NSC reviews enhance SCI by releasing neurotropic factors directly. A substantial quantum of exploration has also shown that glial cell- deduced neurotropic factor (GDNF) can prop in the recovery from SCI. In conclusion, scattered NSCs play a critical part in whim-whams conformation and feeding afters.[10-11] Iwanami, S. Kaneko, M. Nakamura– Transplantation of mortal neural stem cells for spinal cord injury in pri- mates,‖ Journal of Neuroscience Research, vol. 80,no. 2,pp. 182 – 190, 2005.)

4.2 Tissue replacement

Tissue Replacement and Repair Under the stimulation of the internal environment and several nerve development factors, the translocate SCs could differentiate into neurons and glia cells, starting the process of SCI repair and replacement. Following a delayed transplant of NSCs into the injured spinal cord of the patient, it was observed that the transplanted NSCs survived and differentiated into neurons, astrocytes, and oligodendrocytes, and the injury lesion was diminished as compared to the control group.[12]

4.3 Anti inflammatory effects

Effect that reduces inflammation. The anti-inflammatory effects of SC transplantation are another crucial mechanism for treating SCI. To examine the anti-inflammatory effect of the transplanted NSCs into SCI, neutrophils and macrophages were stained, and the mRNA levels of TNF- were found.[14]

4.4 Anti apoptotic Effect: Nearly all neurological illnesses, including SCI, include apoptosis, which is also intimately associated to the restoration of brain function. found that the number ofterminal deoxy nucleoid transferase-mediated DUTP of SCI alone, the number of neurons in SCI, and neurological function were all considerably improved following the transplant of MSCs.[5]

4.5 Promotion of angiogenesis: The restoration of neurological function depends not only on the renewal of nerve cells but also on the support of the microenvironment, which includes blood vessels and extracellular matrix—the development of new blood vessels that aid in tissue healing. Vascular regeneration is a relevant therapeutic study area since it occurs in neurologically damaging illnesses like SCI. The MSC-derived fibronectin and cell adhesion molecules in the extracellular matrix, which is a supportive component of nerve tissue, can encourage nerve repair and axonal regeneration. The repair of neurovascular units is aided by a variety of nutritional elements and molecular building blocks, which together increase neurological function.

5. Application of stem cells for SCI: We concentrate on stem cell treatments with the potential to restore spinal cord function, and a comparison of the various stem cell types is provided.

Types of stem cells the rapeutic mechanism & advantages

Table No 1: Type of stem cell Therapeutic used spinal cord injury.

Type of stem cells	Therapeutic mechanism & advantage	Disadvantage
1. NSCs	• Neuronal replacement therapy • Remylinated demycelinated axon • Secret neurotrophicfactors	1. Undifferentiation ordifferentiation along glial lineage after transplantation ethical constraints
2. MSCs	• Immunomodulation • Anti-apoptic effect • Secret neurotrophicfactors	• Tumorigenicity

	and cytokines • Easily extracted and cultivated	
3. ESCs	• Can be repeatedly passaged in culture • Secret trophic factor	• Immunogenicity
4. Ipscs	• Avioed immune rejection	• Tumorigenicty

6. Common Stem Cells Type for SCI Treatment

6.1 ESssCs: By all-trans retinoic acid induction, ESCs can express neuron-specific antigens; some of these antigens may be glial-specific, and some neuron-like cells may even exhibit acetyl cholinesterase or glutamate decarboxylase activity. There have been numerous publications in recent years on the use of ESC to develop into neurons and glial cells for the treatment of spinal cord injury.[16,17]

6.2 MSCs: MSCs can be extracted from bone marrow, adipose tissue, placenta, amniotic fluid, and umbilical cord. MSCs are multipotent prototype or stromal cells with multilineage potential that can develop into adipocytes, myocytes, osteocytes, and chondrocytes.18 We discuss our most recent knowledge of the uses of mesenchymal stem cells from bone marrow (BMSCs) and adipose tissue (ADSCs) in the treatment of spinal cord injury (SCI) in the current review.[18]

6.3 NSCs: NSCs are multipotent populations that can differentiate into oligodendrocytes, astrocytes, and neurons. The central nervous system (CNS), which includes the subventricular zone, the dentate gyrus of the hippocampus, and the central canal of the spinal cord, is where 16 NSCs are produced.[19,20]

6.4 IPSCs: Reprogramming fully differentiated, mature cells into a pluripotent state yields iPSCs. The benefit of iPSCs is that easily accessible cells, such as skin cells from a case of SCI, might be reprogrammed, distinguished, and dispersed. In 2006, Takahashi and Yamanakacreated aspics. The production of iPSCs from human somatic cells is also possible. A significant advancement in stem cell biology was the capacity to produce pluripotent cells fromadult somatic cells without the use of an embryo.

6.5 NSPCS: NSPCs are found in both fatal and adult CNS. The isolation of adult neural stem cells in mammals was first reported in 1992 by Reynolds and Weiss. Ultmost experimental SCI studies with NSPC transplants have involved rodent cells because mortal

stem cells were moreover not available or delicate to grow. mortal NSPCs have been insulated from fetal brain and spinal cord from aborted fetuses and from adult brain from surgical vivisection samplesand post.

7. Strategies Of SC Therapy for SCI: 7.1 Modes of Therapy. SC transplantation can be done in two different ways: in vivo and in vitro induction. The in vivo environment and particular signaling molecules will guide these SCs into the desired mature cells to perform the necessary functions in the former; in the latter, a specific SC is isolated, cultured, purified, amplified, and induced to differentiate into cells having a desired function in vitro; these mature cells are then transplanted into a human body for treatment. The patient may respond best to the proper fusion of the two approaches.

7.2 Pathways of Transplantation: Transplantation pathways. In many different SCI models, there are numerous strategies to transplant SCs, including intravenous, Tran's arterial, nasal, intraperitoneal, intrathecal, and intramedullary injections. The treatment of SCI was found to be possible using a variety of SC administration techniques. A huge number of cells can be supplied at once via intravenous administration, which is invasive and doesn't harm the spinal cord tissue. NSCs can move to the site of SCI after being given intravenously to SCI rats, develop into neurons and glial cells, and subsequently replace injured cells. After injecting ADMSCs into the veins of SCI rats, Ohta et al. noticed that the rats' motor function also improved as the AD-MSCs gradually accumulated at the location of the SCI.[21]

7.3 Number of SCs: A significant factor impacting the therapeutic outcome is the number of SCs. It will be difficult to exert therapeutic effects with insufficient transplanted cell numbers. The majority of research on SC therapies for SCI employed tens of thousands to millions of cells and shown significant therapeutic benefits.

8. Safety of SC therapy for SCI: It is impossible to overlook the security and dependability of SC therapy for SCI. According to some research, high SCs or infusion rates might result in thrombosis or embolism, which can close up a blood vessel. Other research indicates that transplanted SCs may result in some immunological rejection, hence concurrent immunosuppressive medication is advised. Tumorigenicity and instability are the SC transplant's two most significant adverse effects. NSCs and progenitor cells produced from human-induced multifunctional SCs have unstable DNA methylation patterns, according to This instability gradually manifests with passage. According to Miura et al., mice

BMMSCscan convert spontaneously into cancerous cells and develop fibro sarcoma in vivo. Telomerase activity and chromosomal aberrations may be responsible for this transformation.[22,23]

9. Clinical Application of SC therapy of SCI: Clinical trials have employed a wide range of SCs for the treatment of SCI with the main objective of treating neurologically related conditions and injuries.



Fig no. 5: Clinical Application Stem Cell Therapy.

9.1Clinical Application Stem Cells Therapy: Numerous different type stem cell for treatment of SCI have been used in colourful clinical trials with primary thing treating neurological applicable.

10. Medical Treatment Medical Management: Acute SCI medical operation has come the dependence of treatment alongside surgical intervention in perfecting patient issues. Medical operation for acute SCI includes early addition of mean arterial blood pressure (Chart) ferocious care unit (ICU) operation and forestalment of secondary complications during a case's sanitarium course. Avoidance of hypotension and rigorously clinging to blood

pressure targets in cases with acute SCI serves to maintain acceptable cerebral perfusion pressure and help secondary neuronal injury Optimal spinal cord perfusion is fulfilled with a Chart thing of 85 to 90 mmHg. Grounded upon recommendations from the American Association of Neurological Surgeons Chart pretensions should be maintained for the first 7 days following original injury.

11. Emerging Treatment and Future Directions: Riluzole is a glutamatergic neurotransmission asset with survival benefit in amyotrophic side sclerosis(ALS). Riluzole's mechanisms Over, searching for indispensable treatment modalities that give analogous anti-inflammatory to steroids without its negative side effect profile necessitates further avenues of invention. Several of these arising modalities and composites have been stressed in recent literature, particularly in preclinical studies examining quality of life related issues following SCI.

11.1 Betulinic Acid: Based on inflammatory cascade markers, it has been discovered that BABased on inflammatory cascade markers, it has been discovered that BA treatment reduces pyroptosis, an inflammatory form of programmed cell death. Treatment reduces pyroptosis, an inflammatory form of programmed cell death.[24-25]

11.2 Cannabinoids: Cannabinoids (CBs) and similar chemicals have historically been the participant of restricted federal study in SCI. In addition to being the psychoactive component of marijuana, CB are endogenous substances, and manipulating these receptors may have therapeutic benefits for treating SCI-related emotional disorders and chronic pain. There is historical evidence that CB plays a part in the CNS damage cascade. Arachidonoyl Glycerol (2- Traumatic brain[26] of action isn't fully understood. It's theorized the impact is secondary to a multifactorial process altering synaptic attention of excitatory amino acids. It's proposed to do so by blockage of sodium channels, envenoming both NMDA and non-NMDA receptors, and GABA reuptake inhibition. This benzothiazole class small patch blocks inordinate glutamate release from motor neurons. Dropped glutamate slows the excitotoxic waterfall known to begetneuronal death Riluzole An asset of glutamatergic neurotransmission that helps people with ALS survive is riluzole. The mechanisms of action of riluzole aren't completely understood. The influence, according to proposition, results through a multifactorial process that modifies synaptic attention of excitatory amino acids. It's suggested that this can be fulfilled by inhibitingGABA reuptake, blocking sodium channels, and envenoming both NMDA and non-NMDAreceptors. This

bitsy chemical of the benzothiazole class prevents motor neurons from releasing too important glutamate. The excitotoxic waterfall known to spark neuronal death isbraked by lower glutamate situations.

11.3 Elezanumab: Recent studies have explored Elezanumab impact on functional neurological recovery in the clinical and preclinical environment. The antibody is presently being delved in Phase II clinical trials for multiple sclerosis, acute spinal cord injury, and acute ischemic stroke. In a mice model of noise convinced cochlear damage, RGMa antibody bettered synaptic.[29]

12. Incidence of spinal cord injury

Spinal cord injury is among the most worrying disabilities affiliated to the nervous system. It's considered a global public health problem that affects cases physically, psychologically, and indeed socially likewise, SCI refers to the damage to the SC as a result of some type of degenerative complaint or due to severe trauma; vehicular accidents are generally the most frequent cause of SCI. According to the World Health Organization WHO), it's estimated that each time there are between 40 and new cases per million occupants worldwide of which 90 are of traumatic origin. Nonetheless, the number of cases of non-traumatic origin is constantly adding as well. This prevalence is estimated at10.5 new cases per 100,000 occupants per time. Singh etal. Reported in 2014 that SCI has a advanced frequence in the United States of America with 906 cases per million occupants than in the Rhône- Alpes region, France and Helsinki, Finland, both with.

14. Potential effect of stem cell on a spinal cord repair

After SCI, endogenous regenerative events do, indicating that the spinal cord attempts to repair itself. Schwann cells, the myelinating and rejuvenescence- promoting cell in the supplemental nervous system, resettle from spinal roots into the damaged towel and myelinate spinal cord axons.[31] The expression of rejuvenescence- associated genes is increased in damaged neurons.[32-33] There's a swell in proliferation of original adult stem cells and progenitor cells.[34-35] axonal growth is discomfited by growth inhibitors present on oligodendrocyte myelin debrisand on cells that form scar towel.[36-37]

Also, the invigorated stem cells and progenitor cells don't integrate functionally into the injured spinal cord towel. therefore, the endogenous regenerative events that do after injury fail torepair spinal cord.



Fig no 6: Used stem cell therapy on spinal cord injury.

Spinal cord injury implies that SC microenvironment changes in the early weeks post-injury, such as scar formation; therefore, combined therapies are needed. Animal model studies have shown that stem cell grafts are a potentially effective approach for SC regeneration by substituting necrotic nerve cells with differentiated MSCs, NSCs, and OECs; novel supporting cell transplants for demyelination, re-growth, and connection of the injured axons; and providea protective environment for cells when transplanted into the injury site to prevent further harm by releasing protective substances such as growth factors, decreasing toxins such as free radicals, and preventing the spreading of the injury by reducing inflammation posterior to injury.[38]

15. The role of stem cell in neurological therapy

Several generalities of promoting physiological recovery in SCI using cellular transplant

ways live, and include.

1. Replanting cells to –bridge ‖ axons in the damaged region, to act as a scaffolding for regrowing whim-whams filaments to return, via the stashing of growth and neurotropic factors
2. (Inducing stem cells to form oligodendrocyte precursors to remyelinate damaged axons[37]
3. Removing or inactivating growth inhibitory factors and cells similar as tone- destructive vulnerable cells.

16. Polymer are used in spinal cord repair

Polymer pulpits for SCI form. Biodegradable synthetic polymer pulpits for SCI remedy The main synthetic accoutrements presently used in polymer altar engineering are PCL, PLA, PLGA, and cut Biodegradable compound polymer pulpits have been finagled to not only guide or grease axon rejuvenescence but also alleviate the secondary goods.

16.11 PCL Scaffolds: PCL is biocompatible and biodegradable aliphatic polyester used in numerous medical products similar as towel engineering pulpits, medicine/ gene carriers, and anti-adhesive membranes PCL promotes oligodendrocyte isolation and myelination of axons and is an applicable material.[27,28]

16.2 PLGA Scaffolds: PLA is a polymer of lactic acid, which is easily attained from natural sources and has nontoxic metabolites,. US Food and Drug Administration (FDA) blessing has been attained for several PLA phrasings, thereby making it a promising material for use in medical operations Likewise, PLA and its bifurcation products have been shown to be biocompatible with Schwann cells (SCs).[29,30]

16.3 PEG Scaffolds: PEG, as a water-soluble polymer, inhibits the formation of free radicals, Withstands lipid peroxidation, and counters increases in cell membrane permeability in tissue engineering applications, particularly when employed in the Penumbra of an SCI model.

16.4 PGA Scaffolds: Rat spinal cord injury (SCI) can be treated with a PGA scaffold containing stem cells. According to histopathology findings, spinal cord injuries occurred in animals with coordinated motor control of their tails and hind limb speed.

17. **Order Synthetic Polymer Scaffolds:** When non-biodegradable polymers are used as scaffolds, removal needs a process. Therefore, there hasn't been much usage of this broad

tactic. Acrylic polymers, which include PAN/PVC, PHPMA, and PHEMA, are examples of non- biodegradable polymers. Additionally, because of their electro activity, conductive polymers arecrucial to the repair of SCI.

CONCLUSION

The main goal of stem cell based therapies for spinal cord injury are the neuron replacement andneurological structure and functional restoration after spinal cord injury stem cell - based therapies hold great promise become effective therapeutic approach for spinal cord injury although there different type of stem cell that serve as renewable cell source in cell - based therapies for patient suffering spinal cord injury which type stem cell most suitable for cell replacement therapy in patients with spinal cord injury needed clarified furthermore efficacy and ethical concern stem cell - based replacement therapy continued to challenge Neuron replacement and neurological structure and function repair following spinal cord injury are the primary goals of stem cell-based therapy for spinal cord injuries. Although there are various types of stem cells that serve as renewable cell sources in cell-based therapies for patients suffering from spinal cord injury, which type of stem cell is most suitable for cell replacement therapy in patients with spinal cord injury needs to be clarified. Additionally, the efficacy and ethical issues surrounding stem cell-based replacement therapy continue to pose difficulties.

ACKNOWLEDGEMENT

The author would like to express sincere gratitude to the management of Late Bhagirathi Yashwantrao Pathrikar College of Pharmacy for their continuous support and encouragement in this work.We are very happy for the completion of this project. We would like to express our special thanks of gratitude to our guide Ms. Shubhangi Manikpuriya. Who gave us the golden opportunity to do this wonder full project and here valuable guidance and constant support with all necessary help in our work.

REFERENCE

1. Zhongju Shi1, 2 Hongyun Huang 3 Shiqing Feng Stem cell-based therapies to treat spinal cord injury: Journal of Neurorestoratology, 3 july 2017: 25.
2. N. A. Silva, N. Sousa, R. L. Reis, and A. J. Salgado, –Frombasics to clinical: a comprehensive review on spinal cordinjury,‖ Progress in Neurobiology, 2014; 114: 25–57.
3. M. Stenudd, H. Sabelstrom, and J. Frisen, –Role of endoge-nous neural stem cells in

spinal cord injury and repair,‖JAMA Neurology, 2015; 72(2): 235–237.

4. Ackery A, Tator C, Krassioukov A. A global perspective on spinal cord injury epidemiology. J Neurotrauma, 2004; 21(10): 1355–1370.
5. Farry A, Baxter D. The Incidence and Prevalence of Spinal Cord Injury in Canada: Overviewand estimates based on current evidence.
6. Bain G, Kitchens D, Yao M, Hutten JE, Gottlieb DI. Embryonic stem cells express neuronal properties. Dev. Boil, 1995; 168: 342-57.
7. Odorico JS, Kaufman DS, Thomson JA. Multilineage dif•ferentiation from human embryonic stem cell lines. Stem Cells, 2001; 19: 193-204.
8. Potocnik AJ, Nielsen PJ, Eichmann K. In vitrogeneration of lymphoid precursors from embryonic stem cells. EMBO J., 1994; 13: 5274-83.
9. Akashi K, Traver D, Kondo M, Weissman IL. Lymphoid development from hematopoietic stem cells. In J Hematol, 1999; 69: 217-26.
10. Akashi K, Trover D, Kondo M, Weismann IL. Lymphoid development from hematopoietic stem cells. Int J Hematol, 1999; 69: 217-26.
11. Hodges's and A. R. Harvey, ‒Neurotropic factors used to treat spinal cord injury,‖ Vitamins and Hormones, 2017; 104: 405–457.
12. Iwanami, S. Kaneko, M. Nakamura et al., ‒Transplantationof human neural stem cells for spinal cord injury in pri-mates,‖ Journal of Neuroscience Research, 2017; 80(2).
13. C. S. Abuja, S. Nori, L. Tetreault et al., ‒Traumatic spinal cord injury-repair and regeneration,‖ Neurosurgery, 2017; 80(3S): S9–S22.
14. A. Yamamoto, K. Sakai, K. Matsubara, F. Kano, andM. Ueda, ‒Multifaceted neuro-regenerative activities of human dental pulp stem cells for functional recovery after spinal cordinjury,‖ Neuroscience Research, 2014; 78: 16–20.
15. C. Gu, H. Li, C. Wang et al., ‒Bone marrow mesenchymalstem cells decrease CHOP expression and neuronal apoptosisafter spinal cord injury,‖ Neuroscience Letters, 2017; 636: 282–289.
16. G. Martello and A. Smith, ‒The nature of embryonic stemcells,‖ Annual Review of Cell and Developmental Biology, 2014; 30(1): 647–675.
17. G. Bain, D. Kitchens, M. Yao, J. E. Huettner, and D. I. Gottlieb,―Embryonic stem cells express neuronal properties in vitro,‖Developmental Biology, 1995; 168(2): 342–357.
18. G. C. Kopen, D. J. Prockop, and D. G. Phinney, ‒Marrowstromal cells migrate throughout forebrain and cerebellum, and they differentiate into astrocytes after injection into neo-natal mouse brains, Proceedings of the National Academy of Sciences of the

United States of America, 1999; 96(19): 10711–10716.

19. H. Zhang, X. Fang, D. Huang et al., ‒Erythropoietin signalingincreases neurogenesis and oligodendrogenesis of endoge-nous neural stem cells following spinal cord injury bothin vivo and in vitro,‖ Molecular Medicine Reports, 2018; 17(1): 264–272.
20. P. Lu, Y. Wang, L. Graham et al., ‒Long-distance growth and connectivity of neural stem cells after severe spinal cord injury,‖ Cell, 2012; 150(6): 1264–1273.
21. M. Liadi, A. Collins, Y. Li, and D. Li, ‒The impact of tissue storage conditions on rat olfactory ensheathing cell yieldand the future clinical implications,‖ Cell Transplantation, 2018; 27(9): 1320–1327.
22. J. Deng, Y. Zhang, Y. Xie, L. Zhang, and P. Tang, ‒Cell trans-plantation for spinal cord injury: tumorigenicity of inducedpluripotent stem cell-derived neural stem/progenitor cells, ‖Stem Cells International, 2018; 5653787: 7.
23. S. Nori, Y. Okada, A. Yasuda et al., ‒Grafted human-induced pluripotent stem-cell-derived neurospheres pro-mote motor functional recovery after spinal cord injury in mice,‖ Proceedings of the National Academy of Sciences of the United States of America, 2011; 108(40): 16825–16830.
24. Wu C, Chen H, Zhuang R, Zhang H, Wang Y, et al. Betulinic acid inhibitspyroptosis in spinal cord injury by augmenting autophagy via the AMPK-motor-TFEB signalling pathway. In J Boil Sic., 2021; 17(4): 1138–52.
25. Panikashvili D, Simeonidou C, Ben-Shabat S, Breuer A, Mechoulam R, et al. An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature, 2001; 413(6855): 527– 26. Nevoux J, Alexandru M, Bellocq T, Tanaka L, Hayashi Y, et al. An antibody to RGMa promotes regeneration of cochlear synapses after noise exposure. Sci Rep., 2021; 11(1): 2937.
26. Z. Song, B. Shi, J. Ding, X. Zhuang, X. Zhang, C. Fu, X. Chen, Acomparative study of preventing postoperative tendon adhesion using electrospun polyester membranes with different degradation kinetics, Sci. China: Chem., 2015; 58(7): 1159–1168.
27. O. Suwantong, Biomedical applications of electrospun polycaprolactone fiber mats, Polym. Adv. Technol, 2016; 27(10): 1264–1273.
28. Q. Han, J. Ding, Y. Zheng, X. Zhuang, X. Chen, J. Wang, Hydroxyapatite and vancomycin composited electrospun polylactide mat for osteomyelitis and bone defect treatment, J. Controlled Release, 2015; 213: E92–E92.
29. Z.-Z. Zhang, D. Jiang, S.-J. Wang, Y.-S. Qi, J.-X. Ding, J.-K. Yu, X.-S. Chen, Scaffolds drive meniscus tissue engineering, RSCAdv, 2015; 5(95): 77851–77859.

30. Franklin RJ, Blakemore WF. Requirements for Schwann cell migration within CNS environments: a viewpoint. Review. Int J Dev Neurosci, 1993; 11(5): 641–649.
31. Takami T, Oudega M, Bates ML, Wood PM, Littman N, Bunge MB. Schwann cell but not olfactory ensheathing glia transplants improve hindlimb locomotor performance in the moderately contused adult rat thoracic spinal cord. J Neurosci, 2002; 22(15): 6670–6681.
32. Filbin MT. Myelin-associated inhibitors of axonal regeneration in the adult mammalian CNS. Nat Rev Neurosci, 2003; 4(9): 703–713. [PubMed] [Google Scholar]
33. Gardiner P, Beaumont E, Cormery B. Motoneurones ‐learn‖ and ‐forget‖ physical activity. Review. Can J Appl Physiol, 2005; 30(3): 352–370. [PubMed] [Google
34. Mothe AJ, Tator CH. Proliferation, migration, and differentiation of endogenous ependymalregion stem/progenitor cells following minimal spinal cord injury in the adult rat.Neuroscience, 2005; 131(1): 177–187.
35. Ke Y, Chi L, Xu R, Luo C, Gozal D, Liu R. Early response of endogenous adult neural progenitor cells to acute spinal cord injury in mice. Stem Cells, 2006; 24(4): 1011–1019.
36. Silver J, Millet JH. Regeneration beyond the glial scar. Nat Rev Neurosci, 2004; 5(2): 146–156.
37. Galtrey CM, Asher RA, Nothias F, Fawcett JW. Promoting plasticity in the spinal cord with chondroitinase improves functional recovery after peripheral nerve repair. Brain, 2007; 130((Pt 4)): 926–939.